Dr Ashraf Azzabi
| Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial | 2023 |
|
Dr Rachel Pearson Dr Ashraf Azzabi
| Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life | 2020 |
|
Dr Ashraf Azzabi
| 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial | 2018 |
|
Dr Ashraf Azzabi
| SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer | 2018 |
|
Dr Rachel Pearson Professor Peter Thelwall Jim Snell Dr Piotr Pieniazek Professor Rakesh Heer et al. | Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study | 2016 |
|
Dr Rachel Pearson Professor Peter Thelwall Jim Snell Dr Piotr Pieniazek Professor Rakesh Heer et al. | Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study | 2016 |
|
Dr James Wilson Dr Ashraf Azzabi Dr Jacqueline Stockley Professor Naeem Soomro Garrett Durkan et al. | Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer | 2015 |
|
Stuart Robinson John Moir Dr Ashraf Azzabi Professor Derek Manas Steven White et al. | Defining the optimal conversion chemotherapy regimen for patients with inoperable liver only metastases from colorectal cancer - a systematic review and meta-analysis | 2014 |
|
Dr Ashraf Azzabi
| Stage I testicular tumor: How frequently to scan? | 2014 |
|
Dr Ashraf Azzabi Dr Andrew Hughes Dr Paula Calvert Professor Ruth Plummer Melanie Griffin et al. | Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations | 2005 |
|
Dr Andrew Hughes Dr Paula Calvert Dr Ashraf Azzabi Professor Ruth Plummer Melanie Griffin et al. | Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma | 2002 |
|
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al. | Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) | 2002 |
|
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al. | Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) | 2002 |
|
Dr Andrew Hughes Dr Ashraf Azzabi Professor Ruth Plummer Dr Jane Margetts Kevin Fishwick et al. | A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate). | 2001 |
|
Dr Paula Calvert Dr Ashraf Azzabi Dr Andrew Hughes Professor Ruth Plummer Angela Robinson et al. | A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. | 2000 |
|